TrialThe Journal of dermatology2018

Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.

Shigetoshi Sano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.